Report error Found 612 Enz. Inhib. hit(s) with all data for entry = 9218
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Human)
Infinity Pharmaceuticals
US Patent
Infinity Pharmaceuticals
US Patent
Affinity DataIC50: 25.5nMAssay Description:A compound's ability in selectively inhibiting PI3K-γ can be assessed using RAW264.7 macrophages. Briefly, serum-starved RAW264.7 cells are ...More data for this Ligand-Target Pair

















































